Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Type 1 diabetes occurs when the body's immune system attacks and destroys the insulin-producing cells, leading to unregulated ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

In the meantime, Novo Nordisk has responded to the threat from the cut-price fast and long-acting insulins with newer insulins that aim to improve on the performance of the established rivals.

providing a background level of blood glucose control that can sometimes be topped up at mealtimes with fast-acting insulins. The results of the ONWARDS 2 trial of insulin icodec showed that it ...

Magnesium can lower blood pressure by relaxing blood vessels and counteracting the damage they endure. However, research is ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

President Donald Trump didn't wait long in his second term to begin shaking things up in Washington, D.C. In less than two weeks back in the White House, Trump delivered upheaval in multiple areas, ...